PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known	
Application Number	10/670,065
Filing Date	9/24/2003
First Named Inventor	Markovitz et al.
Art Unit	1641
Examiner Name	Cook
Attorney Docket Number	UM-08388

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	1	WO 98/39298	09/03/1998	Sharon	whole document	
	2	WO 05/012872 A2	02/10/2005	Isreal	whole document	
	3	DT 1810423				

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 9

	Complete if Known
Application Number	10/670,065
Filing Date	9/24/2003
First Named Inventor	Markovitz et al.
Art Unit	1641
Examiner Name	Cook
Attorney Docket Number	UM-08388

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	3	Traub, P. Intermediate Filaments A Review, (Springer-Verlag, New York, Tokyo, 1985).	
	4	Fuchs, E. & Weber, K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 63, 345-82 (1994).	
	5	Christian, J.L., Edelstein, N.G. & Moon, R.T. Overexpression of wild-type and dominant negative mutant vimentin subunits in developing Xenopus embryos. New Biol 2, 700-11. (1990).	
	6	Colucci-Guyon, E. et al. Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell 79, 679-94. (1994).	
	7	Eckes, B. et al. Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J Cell Sci 111, 1897-907 (1998).	
	8	Galou, M. et al. Disrupted glial fibrillary acidic protein network in astrocytes from vimentin knockout mice. J Cell Biol 133, 853-63. (1996).	
	9	Eckes, B. et al. Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci 113, 2455-62 (2000).	
	10	Cain, H., Kraus, B., Krauspe, R., Osborn, M. & Weber, K. Vimentin filaments in peritoneal macrophages at various stages of differentiation and with altered function. Virchows Arch B Cell Pathol Incl Mol Pathol 42, 65-81 (1983).	
	11	Rius, C., Cabanas, C. & Aller, P. The induction of vimentin gene expression by sodium butyrate in human promonocytic leukemia U937 cells. Exp Cell Res 188, 129-34 (1990).	
	12	Rius, C. & Aller, P. Vimentin expression as a late event in the in vitro differentiation of human promonocytic cells. J Cell Sci 101, 395-401 (1992).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 8

Complete if Known	
Application Number	10/670,065
Filing Date	9/24/2003
First Named Inventor	Markovitz et al.
Art Unit	1641
Examiner Name	Cook
Attorney Docket Number	UM-08388

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	13	Reddy, V.Y., Zhang, Q.Y. & Weiss, S.J. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc Natl Acad Sci U S A 92, 3849-53 (1995).	
	14	Punturieri, A. et al. Regulation of Elastinolytic Cysteine Proteinase Activity in Normal and Cathepsin K-deficient Human Macrophages. J Exp Med 192, 789-800 (2000).	
	15	Cain, H., Krauspe, R. & Kraus, B. The cytoskeleton in activated and in functionally disordered cells of the macrophage system. Pathol Res Pract 175, 162-79 (1982).	
	16	Gao, Y. & Sztul, E. A novel interaction of the Golgi complex with the vimentin intermediate filament cytoskeleton. J Cell Biol 152, 877-94. (2001).	
	17	Traub, P. Large scale isolation, purification, and partial characterization of the intermediate filament-specific, Ca2 +-activated proteinase from porcine kidney and Ehrlich ascites tumor cells: a comparative study. Arch Biochem Biophys 228, 120-32. (1984).	
	18	Traub, P., Scherbarth, A., Willingale-Theune, J., Paulin-Levasseur, M. & Shoeman, R. Differential sensitivity of vimentin and nuclear lamins from Ehrlich ascites tumor cells toward Ca2+ -activated neutral thiol proteinase. Eur J Cell Biol 46, 478-90. (1988).	
	19	Yoshida, H., Murachi, T. & Tsukahara, I. Degradation of actin and vimentin by calpain II, a Ca2+-dependent cysteine proteinase, in bovine lens. FEBS Lett 170, 259-62. (1984).	
	20	Perides, G., Kuhn, S., Scherbarth, A. & Traub, P. Probing of the structural stability of vimentin and desmin-type intermediate filaments with Ca2+-activated proteinase, thrombin and lysine-specific endoproteinase Lys-C. Eur J Cell Biol 43, 450-8. (1987	
	21	Tozser, J. et al. Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates. Eur J Biochem 265, 423-9. (1999).	
	22	Ben-Ze'ev, A., Babiss, L.E. & Fisher, P.B. Cleavage of vimentin in dense cell cultures. Inhibition upon transformation by type 5 adenovirus. Exp Cell Res 166, 47-62. (1986).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 9

Complete if Known	
Application Number	10/670,065
Filing Date	9/24/2003
First Named Inventor	Markovitz et al.
Art Unit	1641
Examiner Name	Cook
Attorney Docket Number	UM-08388

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	23	Belin, M.T. & Boulanger, P. Processing of vimentin occurs during the early stages of adenovirus infection. J Virol 61, 2559-66. (1987).	
	24	Cheng, T.J. & Lai, Y.K. Identification of mitogen-activated protein kinase-activated protein kinase-2 as a vimentin kinase activated by okadaic acid in 9L rat brain tumor cells. J Cell Biochem 71, 169-81. (1998).	
	25	Turowski, P., Myles, T., Hemmings, B.A., Fernandez, A. & Lamb, N.J. Vimentin dephosphorylation by protein phosphatase 2A is modulated by the targeting subunit B55. Mol Biol Cell 10, 1997-2015 (1999).	
	26	Yasui, Y. et al. Protein kinases required for segregation of vimentin filaments in mitotic process. Oncogene 20, 2868-76. (2001).	
	27	Lo, C.-J., Fu, M. & Cryer, H.G. Interleukin 10 Inhibits Alveolar Macrophage Production of Inflammatory Mediators Involved in Adult Respiratory Distress Syndrome. Journal of Surgical Research 79, 179-184 (1998).	
	28	Bhattacharyya, S., Ghosh, S., Jhonson, P.L., Bhattacharya, S.K. & Majumdar, S. Immunomodulatory Role of Interleukin-10 in Visceral Leishmaniasis: Defective Activation of Protein Kinase C-Mediated Signal Transduction Events. Infect. Immun. 69, 1499-1507 (2001).	
	29	Bogdan, C., Vodovotz, Y. & Nathan, C. Macrophage deactivation by interleukin 10. J Exp Med 174, 1549-55. (1991).	
	30	Schlosser-Silverman, E., Elgrably-Weiss, M., Rosenshine, I., Kohen, R. & Altuvia, S. Charactenzation of Escherichia coli DNA lesions generated within J774 macrophages. J Bacteriol 182, 5225-30 (2000).	
	31	Klymkowsky, M.W., Bachant, J.B. & Domingo, A. Functions of intermediate filaments. Cell Motil Cytoskeleton 14, 309-31 (1989).	
	32	Lehto, V.P., Hovi, T., Vartio, T., Badley, R.A. & Virtanen, I. Reorganization of cytoskeletal and contractile elements during transition of human monocytes into adherent macrophages. Lab Invest 47, 391-9 (1982).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 9

Complete if Known	
Application Number	10/670,065
Filing Date	9/24/2003
First Named Inventor	Markovitz et al.
Art Unit	1641
Examiner Name	Cook
Attorney Docket Number	UM-08388

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	33	Owen, P.J., Johnson, G.D. & Lord, J.M. Protein kinase C-delta associates with vimentin intermediate filaments in differentiated HL60 cells. Exp Cell Res 225, 366-73 (1996).	
	34	Chu, J.J. et al. Taxol induces concomitant hyperphosphorylation and reorganization of vimentin intermediate filaments in 9L rat brain tumor cells. J Cell Biochem 68, 472-83. (1998).	
	35	Szalay, J. et al. Associations of PKC isoforms with the cytoskeleton of B16F10 melanoma cells. J Histochem Cytochem 49, 49-66. (2001).	
	36	Shoeman, R.L. et al. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc Natl Acad Sci U S A 87, 6336-40. (1990).	
	37	Kontny, E., Kurowska, M., Szczepanska, K. & Maslinski, W. Rottlerin, a PKC isozyme-selective inhibitor, affects signaling events and cytokine production in human monocytes. J Leukoc Biol 67, 249-58. (2000).	
	38	Hansson, G.K., Lagerstedt, E., Bengtsson, A. & Heideman, M. IgG binding to cytoskeletal intermediate filaments activates the complement cascade. Exp Cell Res 170, 338-50 (1987).	
	39	Sanchez, A., Ossorio, C., Alvaro-Gracia, J.M., Padilla, R. & Avila, J. A subset of antibodies from the sera of patients with systemic lupus erythematosus react with vimentin and DNA. J Rheumatol 17, 205-9 (1990).	
	40	Senecal, J.L. & Rauch, J. Hybridoma lupus autoantibodies can bind major cytoskeletal filaments in the absence of DNA-binding activity. Arthritis Rheum 31, 864-75 (1988).	
	41	Franch, A., Castellote, C., Vila, J.L., Vilaro, S. & Castell, M. Anticytoskeletal autoantibody development in adjuvant arthritis. J Rheumatol 21, 489-97 (1994).	
	42	Lane, B.R. et al. TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. J Immunol 163, 3653-61 (1999).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 9

	Complete if Known
Application Number	10/670,065
Filing Date	9/24/2003
First Named Inventor	Markovitz et al.
Art Unit	1641
Examiner Name	Cook
Attorney Docket Number	UM-08388

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	43	Terasaki, M. & Reese, T.S. Characterization of endoplasmic reticulum by co-localization of BiP and dicarbocyanine dyes. J Cell Sci 101, 315-22. (1992).	
	44	Matsukawa, A. et al. Pivotal role of the CC chemokine, macrophage-derived chemokine, in the innate immune response. J Immunol 164, 5362-8 (2000)	
	45	Cherry et al., Enzyme-Linked Fluorescent Detection For Automated Multiplex DNA Sequencing, Genomics 20, 68074 (1994)	
	46	Schmitt et al., Expression of Gene 1.2 and Gene 10 of Bacteriophage T7 Is Lethal to F Plasmid-Containing Escherichia coli, J of Bacteriology 173, 1536-1543 (1991)	
	47	Slilaty et al., Accurate insertional inactivation of lacZa: construction of pTrueBlue and M13TrueBlue cloning vectors, Gene 213, 83-91 (1998)	
	48	Henrich et al., Use of the I ysis gene of bacteriophage oX174 for the contruction of a positive selection vector, Gene 42, 345-349 (1986)	
	49	Viera et al., The pUC plasmids, anM13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers, Gene 19, 259-268 (1982)	
	50	Quandt et al., Versatile suicide vectors which allow direct selection for gene replacement in Gram-negative bacteria, Gene 127, 15-21 (1993)	
	51	Wiemann et al., Simultaneous On-Line DNA Sequencing on Both Strands with Two Fluorescent Dyes, Analytical Biochemistry 224, 117-121 (1995)	
	52	Bernard et al., Positive-selection vectors using the F plasmid ccdB killer gene, Gene 148, 71-74 (1994)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 9

Complete if Known	
Application Number	10/670,065
Filing Date	9/24/2003
First Named Inventor	Markovitz et al.
Art Unit	1641
Examiner Name	Cook
Attorney Docket Number	UM-08388

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	53	Dillard et al., Analysis of Strepococcus pneumoniae Sequences Cloned into Escherichia coli: Effect of Promoter Strength and Transcription Terminators, J of Bacteriology 173, 5105-5109 (1991)	
	54	Geider et al., A plasmid cloning system utilizing replication and packaging functions of the filamentous bacterio-phage fd, Gene 33, 341-349 (1985)	
	55	Smith et al., fluorescence detection in automated DNA sequence analysis, Nature 321, 674-679 (1986)	
	56	Reynolds et al., Parameters Affecting Transcription Termination by Escherichia coli RNA Polymerase, J Mol Biol 224, 31-51 (1992)	
	57	Hoffmann-Berling, Virology 22, 305-313 (1964)	
	58	Church et al., Multiplex DNA Sequencing, Science 240, 185-188 (1988)	
	59	Prober et al., A System for Rapid DNA Sequencing with Fluorescent Chain-Terminating Dideoxynucleotides, Science 238, 336-341 (1987)	
	60	Wiemann et al., "Doublex" Fluorescent DNA Sequencing: Two Independent Sequences Obtained Simultaneously in One Reaction with Internal Labeling and Unlabeled Primers, Analytical Biochemistry 234, 166-174 (1996)	
	61	Egholm et al., PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules, Nature 365, 566-568 (1993)	
	62	Sanger et a., DNA sequencing with chain-terminating inhibitors, PNAS 74, 5463-5467 (1977)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 9

Complete if Known	
Application Number	10/670,065
Filing Date	9/24/2003
First Named Inventor	Markovitz et al.
Art Unit	1641
Examiner Name	Cook
Attorney Docket Number	UM-08388

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	63	Lipman et al., A tool for multiple sequence alignment, PNAS 86, 4412-4415 (1989)	
	64	Fitzgerald et al., Rapid shotgun cloning utilizing the two base recognition endonucleases CviJ1, Nucleic Acids Research 20, 3753-3762 (1992)	
	65	Rose, Nucleic Acids Research 16, 355 (1988)	
	66	Tabor et al., A single residue in DNA polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy-and dideoxyribonucleotides, PNAS 92, 6339-6343 (1995)	
	67	Chen et al., Cloning of Streptococcus pneumoniae DNA fragments in Escherichia coli requires vectors protected by strong transcriptional terminatores, Gene 55, 179-187 (1987)	
	68	Bolivar et al., Construction and Characterization of New Cloning Vehicles, Gene 2, 95-113 (1977)	
	69	Liu et al., An Efficient Method for Blunt-End Ligation of PCR Products, Biotechniques 12, 28-29 (1992)	
	70	Creasey et al., Application of a Novel Chemiluminescence-Based DNA Detection Method to Single-Vector and Multiplex DNA Sequencing, BioTechniques 11, 102-109 (1991)	
	71	Neurath et al., Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in Mice, J of Ex Med 182, 1281-1290 (1995)	
	72	Chen et al., Construction and properties of a new insertion vector, pJDC9, that is protected by transcriptional terminators and useful for cloning of DNA from Streptococcus pneumoniae, Gene 64, 155-164 (1988)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 9

	Complete if Known
Application Number	10/670,065
Filing Date	9/24/2003
First Named Inventor	Markovitz et al.
Art Unit	1641
Examiner Name	Cook
Attorney Docket Number	UM-08388

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	73	Podor et al., Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface, J. Biol Chem 277(9):7529 (2002)	
	74	Perides et al., Electrostatic and hydrophobic interactions of the intermediate filament protein vimentin and its amino terminus with lipid bilayers, J Biol Chem 262:13742-13749 (1987)	
	75	Nishimura et al., A di-acidic signal required for selective export from the endoplasmic reticulum, Science 277:556-559 (1997)	
	76	Nishimura et al., A di-acidic (DXE) code directs concentration of cargo during export from the endoplasmic reticulum, J Biol Chem274:15937-15946 (1999)	
	77	Hansson et al., Fc-mediated binding of IgG to vimentin-type intermediate filaments in vascular endothelial cells, PNAS USA 81:3103-3107 (1984)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.